Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Kyverna Therapeutics Inc. (NASDAQ: KYTX) closed at $6.39 in the last session, down -7.66% from day before closing price of $6.92. In other words, the price has decreased by -$7.66 from its previous closing price. On the day, 0.8 million shares were traded. KYTX stock price reached its highest trading level at $6.92 during the session, while it also had its lowest trading level at $6.3.
Ratios:
We take a closer look at KYTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 14.86 and its Current Ratio is at 14.86. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 03, 2024, initiated with a Neutral rating and assigned the stock a target price of $8.
On March 04, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $44.
On March 04, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.Morgan Stanley initiated its Overweight rating on March 04, 2024, with a $40 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 12 ’24 when Vida Ventures, LLC bought 253,136 shares for $22.00 per share. The transaction valued at 5,568,992 led to the insider holds 252,553 shares of the business.
Bain Capital Life Sciences Inv bought 450,000 shares of KYTX for $9,900,000 on Feb 12 ’24. The 10% Owner now owns 3,163,868 shares after completing the transaction at $22.00 per share. On Feb 12 ’24, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 910,000 shares for $22.00 each. As a result, the insider paid 20,020,000 and bolstered with 4,126,119 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYTX now has a Market Capitalization of 275708672 and an Enterprise Value of -60529616.
Stock Price History:
Over the past 52 weeks, KYTX has reached a high of $35.06, while it has fallen to a 52-week low of $6.30. The 50-Day Moving Average of the stock is -20.14%, while the 200-Day Moving Average is calculated to be -58.63%.
Shares Statistics:
According to the various share statistics, KYTX traded on average about 477.16K shares per day over the past 3-months and 408730 shares per day over the past 10 days. A total of 43.12M shares are outstanding, with a floating share count of 17.68M. Insiders hold about 59.03% of the company’s shares, while institutions hold 37.38% stake in the company. Shares short for KYTX as of 1724976000 were 2681677 with a Short Ratio of 5.62, compared to 1722384000 on 2936468. Therefore, it implies a Short% of Shares Outstanding of 2681677 and a Short% of Float of 11.2399995.
